Second Quarter of the Fiscal Year Ending March 31, 2025
Sales composition ratio
Pharmaceutical Wholesale Business
In the six months ended September 30, 2024, the net sales of the pharmaceutical wholesale business increased slightly, reflecting sales of products eligible for the price maintenance premium, such as anticancer drugs, original drugs, the cervical cancer vaccine and the COVID-19 vaccine that will begin to be given to patients in October, which offset the loss of revenue due to the impact of the NHI drug price revision and the negative impact of matters in other areas such as the year-on-year decline in sales of COVID-19-related products (sales of
drugs, test kits, etc. for the treatment of COVID-19 and sales from the government-commissioned delivery of COVID-19 vaccines). Profit grew year on year, mainly due to the effect of this sales growth.
As a result, net sales were ¥279,541 million (100.8% of that of the same period of the previous year), and segment profit (operating profit) was ¥2,724 million (103.2% of that of the same period of the previous year).
Pharmacy Business
The pharmacy business achieved sales growth, mainly due to efforts to expand income from dispensing technical fees and income from pharmaceutical management fees, despite a decrease in the the number of prescriptions received. However, profit fell, mainly due to the impact of NHI drug price revisions and longer duration prescriptions. As a result, net sales were ¥9,725 million (103.6% of that of the same period of the previous year), and segment profit (operating profit) was ¥96 million (83.7% of that of the same period of the previous year).
Veterinary Drug Wholesale Business
The veterinary drug wholesale business recorded net sales of ¥5,647 million (101.0% of that for the same period of the previous year), partly due to the conversion of Arrowmedical Inc. into a consolidated subsidiary, which offset the sometimes negative impact of a changeover in products after certain products started being sold directly by their manufacturers. Segment profit (operating profit) was ¥144 million (78.6％ of that for the same period of the previous year), reflecting the impact of higher purchase prices.
Other Businesses
Other businesses reported a smaller segment loss, mainly due to the recovery of sales in each business. As a result, net sales were ¥2,165 million (106.4% of the level for the same period of the previous year), and segment loss (operating loss) was ¥88 million (compared to operating loss of ¥108 million for the same period of the previous year).